2.91
前日終値:
$2.78
開ける:
$2.85
24時間の取引高:
895.06K
Relative Volume:
0.90
時価総額:
$485.68M
収益:
-
当期純損益:
$-54.70M
株価収益率:
-8.8182
EPS:
-0.33
ネットキャッシュフロー:
$-51.36M
1週間 パフォーマンス:
+3.19%
1か月 パフォーマンス:
+18.29%
6か月 パフォーマンス:
-31.37%
1年 パフォーマンス:
-41.57%
Savara Inc Stock (SVRA) Company Profile
SVRA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
SVRA
Savara Inc
|
2.91 | 485.68M | 0 | -54.70M | -51.36M | -0.33 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-20 | 開始されました | Wells Fargo | Overweight |
2024-11-13 | ダウングレード | Evercore ISI | Outperform → In-line |
2024-02-15 | 開始されました | JMP Securities | Mkt Outperform |
2023-11-07 | 開始されました | Guggenheim | Buy |
2023-05-16 | アップグレード | Jefferies | Hold → Buy |
2023-03-31 | ダウングレード | Jefferies | Buy → Hold |
2021-03-16 | 開始されました | Piper Sandler | Overweight |
2021-03-15 | 開始されました | Oppenheimer | Outperform |
2019-06-13 | 繰り返されました | H.C. Wainwright | Buy |
2019-06-13 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
2019-06-13 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
2018-08-13 | 再開されました | ROTH Capital | Neutral |
2018-01-03 | 開始されました | Ladenburg Thalmann | Buy |
2017-09-27 | 再開されました | ROTH Capital | Buy |
2017-09-22 | 開始されました | Jefferies | Buy |
2017-09-11 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Savara Inc (SVRA) 最新ニュース
Savara stock holds Buy rating, $6 target from H.C. Wainwright - Investing.com India
Charles Schwab Investment Management Inc. Grows Position in Savara Inc (NASDAQ:SVRA) - Defense World
Savara enters loan and security agreement with Hercules Capital - MSN
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update - Joplin Globe
JMP maintains $9 target on Savara stock, sees FDA nod By Investing.com - Investing.com South Africa
JMP maintains $9 target on Savara stock, sees FDA nod - Investing.com India
Savara secures $200M loan to support respiratory drug launch By Investing.com - Investing.com South Africa
Savara secures $200M loan to support respiratory drug launch - Investing.com
Savara Gets Up to $200 Million Loan From Hercules Capital - Marketscreener.com
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital - Bluefield Daily Telegraph
Major Financial Boost: Savara Lands $200M Debt Deal as FDA Decision Approaches - StockTitan
Savara submits FDA application for aPAP therapy MOLBREEVI - Investing.com
Savara Completes Submission Of The Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For MOLBREEVI As A Treatment For Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Marketscreener.com
Breakthrough: First Treatment for Rare Lung Disease aPAP Heads to FDA Review - StockTitan
Bank of New York Mellon Corp Purchases 17,870 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ: SVRA) Stock: Investors Need To Know This - Stocks Register
Victory Capital Management Inc. Reduces Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Savara Inc (NASDAQ:SVRA) Receives $8.83 Consensus Price Target from Analysts - Defense World
Savara Inc. to Present at Leerink Global Healthcare Conference - MSN
Breakthrough Phase 3 Results: New Treatment Reduces Lung Procedures in Rare Disease Patients - StockTitan
Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease - MSN
Oppenheimer & Co. Inc. Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
Rhumbline Advisers Purchases 9,041 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ: SVRA): An Enticing Stock To Watch - Stocks Register
Savara, Inc. to Host Earnings Call - ACCESS Newswire
Savara Launches Test for Autoimmune Lung Disease in US; Shares Up Pre-Bell -March 06, 2025 at 08:55 am EST - Marketscreener.com
Savara Announces U.S. Launch of the aPAP ClearPath Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire
Game-Changing Finger-Prick Test Could Transform Rare Lung Disease DiagnosisWhat Makes It Special? - StockTitan
Savara Announces Participation in the Leerink Global Healthcare Conference - Joplin Globe
Rare Disease Biotech Savara Sets Key Investor Presentation at Leerink Conference - StockTitan
Savara (SVRA) Expected to Announce Earnings on Thursday - Defense World
Savara Insiders Lose Out As Stock Sinks To US$2.56 - Simply Wall St
SVRA stock touches 52-week low at $2.58 amid market challenges - Investing.com Australia
SVRA stock touches 52-week low at $2.58 amid market challenges By Investing.com - Investing.com South Africa
Analysts Set Savara Inc (NASDAQ:SVRA) Price Target at $9.86 - Defense World
Savara Inc. Awards Stock Options and RSUs to New Employees - MSN
SVRASavara Inc Latest Stock News & Market Updates - StockTitan
Savara Announces New Employment Inducement Grant - Milton Daily Standard
Savara's Latest Executive Compensation Package Revealed: Key Details on New Employee Stock Awards - StockTitan
A company insider recently sold 25,000 shares of Savara Inc [SVRA]. Should You Sale? - Knox Daily
SG Americas Securities LLC Has $158,000 Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
SVRA’s latest rating updates from top analysts. - Knox Daily
Positive Signs As Multiple Insiders Buy Savara Stock - Yahoo Finance UK
Investing in Savara Inc (SVRA) Is Getting More Attractive - Knox Daily
Savara Inc. to Present at Upcoming Healthcare Investor Conferences - MSN
Savara Inc. Publishes Promising Long-Term Outcomes for aPAP Treatment - MSN
Savara Inc (SVRA) 財務データ
収益
当期純利益
現金流量
EPS
Savara Inc (SVRA) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Pauls Matthew | CHIEF EXECUTIVE OFFICER |
Dec 16 '24 |
Sale |
3.31 |
54,702 |
180,828 |
1,536,379 |
Hawkins Richard J | Director |
Dec 16 '24 |
Sale |
3.32 |
8,000 |
26,569 |
67,241 |
大文字化:
|
ボリューム (24 時間):